MedTrace Logo

Efficacy and Safety of Apremilast in Psoriasis

NCT06032858 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2023-09-13

No results posted yet for this study

Summary

Psoriasis is a long standing inflammatory, autoinflammatory disease linked with many comorbidities. Patients with moderate to severe plaque psoriasis can be managed with topical as well as systemic medications. FDA approved Apremilast as first drug to be taken orally in cases of psoriasis in mid 1990's. Currently, according to researchers best knowledge no study has been done on use of Apremilast in Pakistan. It has recently become available here. Keeping in view all the benefits of this drug, a study has been planned to check its effectiveness and safety 30mg twice a day, in patients with moderate to severe chronic plaque psoriasis based on Psoriasis area and severity index and Body surface area assessments in our population.

Conditions

Interventions

DRUG

Apremilast 30mg

Apremilast 30mg twice daily

Sponsors & Collaborators

  • Ghurki Trust and Teaching Hospital

    lead OTHER

Principal Investigators

  • Prof. Dr. Haroon Nabi · Professor Department of Dermatology LMDC

  • Dr. Saira Muaaz · Department of Dermatology Ghurki Hospital

  • Dr. Hira Tariq · Senior Registrar Department of Dermatology Services Hospital

  • Dr. Sumera Hanif · Senior Registrar Department of Dermatology LMDC

  • Dr. Talat Akbar · Associate Professor, Dermatology, LMDC

  • Prof. Dr. Faria Asad · Head of Department Dermatology SIMS/ Services Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
59 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-03-06
Primary Completion
2023-07-10
Completion
2023-08-10

Countries

  • Pakistan

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06032858 on ClinicalTrials.gov